valspodar

also known as PSC-833 · Amdray · NSC# 648265 · SDZ PSC 833

Protein / enzyme biologic targets ABCB1 via inhibition

Developed for: breast cancer · leukemia · acute megakaryoblastic leukemia in adult · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia with t(8;21)(q22;q22) translocation
+16 more
· acute myeloid leukemia, del(5q31-q32) · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myelomonocytic leukemia M4 · adult acute monocytic leukemia · kidney neoplasm · lymphoma · ovarian cancer · acute erythroid leukemia · acute leukemia · metastatic malignant neoplasm · metastatic neoplasm · myelodysplastic syndrome · plasma cell myeloma · renal cell carcinoma · acute myeloid leukemia
Investigated by: National Cancer Institute (NCI) · Eastern Cooperative Oncology Group · SWOG Cancer Research Network · Cancer and Leukemia Group B · City of Hope Medical Center · European Organisation for Research and Treatment of Cancer - EORTC
+2 more
· Leukemia Research Fund · NCIC Clinical Trials Group

Trials 12 · a red edge is where a trial was stopped

today NCT00006363 · Ph 3 NCT00004217 · Ph 2 NCT00005823 · Ph 3 NCT00003190 · Ph 3 NCT00002826 · Ph 2 NCT00002878 · Ph 3 NCT00001570 · Ph 1 NCT00002925 · Ph 1/2 NCT00002912 · Ph 1 NCT00002937 · Ph 2 NCT00001383 · Ph 1 NCT00001302 · Ph 1

199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT00001570	Feb 1997 → Jan 2001	kidney neoplasm, metastatic malignant neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00002912	Jan 1997 → Mar 2006	acute leukemia	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00001383	Mar 1994 → Jan 2001	breast cancer, lymphoma, ovarian cancer, renal cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00001302	Sep 1992 → Jun 2002	breast cancer, kidney neoplasm, lymphoma, metastatic neoplasm +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00002925	Feb 1997 → Nov 2003	leukemia	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 23 trials
Phase 2	NCT00004217	Feb 2000 → May 2001	leukemia	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 2	NCT00002826	Aug 1997 → Nov 2003	breast cancer	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 2	NCT00002937	Jun 1996 → Nov 2005	breast cancer	City of Hope Medical Center	Completed	No outcome recorded
Phase 34 trials
Phase 3	NCT00006363	Nov 2000 → Jun 2005	acute basophilic leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +12	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 3	NCT00005823	Dec 1998 → Dec 2007	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Leukemia Research Fund	Completed	No outcome recorded
Phase 3	NCT00003190	Jan 1998 → Aug 2002	acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +8	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 3	NCT00002878	Jun 1997 → Apr 2003	plasma cell myeloma	Eastern Cooperative Oncology Group	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT00003207 Background	Mar 1998 → Jul 2002	cancer of unknown primary site, sarcoma	Washington University School of Medicine	Completed	No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

Field	Value	Cited text
Known as	valspodar	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002912 ↗ 7 NCT00002937 ↗ NCT00002878 ↗ NCT00006363 ↗ NCT00004217 ↗ NCT00005823 ↗ NCT00002826 ↗ NCT00003190 ↗
Known as	Amdray	ChEMBL registry synonym — accepted as the source's own label CHEMBL1086218 ↗
Known as	NSC# 648265	“PSC-833 (NSC# 648265)” NCT00002925 ↗
Known as	PSC-833	“Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.” PMID 20209646 ↗ May 2010 6 “Preliminary studies have shown valspodar (PSC-833: Novartis Pharmaceuticals, East Hanover, NJ) to be a potent inhibitor of multidrug resistance (MDR)” PMID 16419071 ↗ Feb 2006 NCT00001383 ↗ NCT00001302 ↗ NCT00001570 ↗ NCT00003207 ↗ NCT00002925 ↗
Known as	SDZ PSC 833	ChEMBL registry synonym — accepted as the source's own label CHEMBL1086218 ↗
Action	Inhibit	“the P-glycoprotein Antagonist PSC 833” NCT00001302 ↗ 1 “P-glycoprotein 1 inhibitor” CHEMBL1086218 ↗
Modality	Protein / enzyme biologic	— CHEMBL1086218 ↗
Route	Oral	“oral PSC 833” NCT00001383 ↗
Target	ABCB1	“P-glycoprotein 1 inhibitor” CHEMBL1086218 ↗